Antioxidant and Hepatoprotective Activity of a New Tablets Formulation from Tamarindus indica L.

Table 3

Effect of Tamarindus indica L. tablets on serum biochemical markers of liver function in CCl₄ induced hepatotoxicity in Sprague Dawley rats.

Group	ALT (UI/L)	AST (UI/L)	ALP (UI/L)	GGT (UI/L)	TB (mg/100 mL)	TP (g/100 mL)
I	32.56 2.05	21.37 0.59	187.32 3.08	86.18 3.86	3.09 0.04	7.12 0.47
II	326.78 19.31	95.97 4.41	426.53 3.31	161.30 7.90	6.57 0.09	5.26 0.37
III	36.33 0.94	37.27 5.64	204.56 2.90	98.10 1.40	4.84 0.25	8.29 0.22
IV	38.62 0.98	38.67 2.50	246.76 3.10	111.10 1.19	5.21 0.17	7.41 0.23
V	33.49 0.91	25.38 2.38	202.51 4.96	99.09 3.34	5.15 0.06	8.33 0.34

ALT: alanine aminotransferase, AST: aspartate aminotransferase, ALP: alkaline phosphatase, GGT: -glutamyl transpeptidase, TB: total bilirubin, and TP: total protein.
I: control group; II: CCl₄ induced hepatotoxicity group; III: Silymarin treated group; IV and V: Tamarindus indica L. tablets treated groups at doses 100 mg/kg and 200 mg/kg, respectively.
Different letters on columns indicate significant statistical differences in Tukey HSD test.
Data are expressed as mean SD; .